Pharmaceutical News

RSS

Genzyme receives EC approval for Thyrogen product label expansion

Genzyme, a Sanofi company, today announced it has received European Commission approval of a product label expansion for the use of Thyrogen (thyrotropin alfa) with a wider irradiation dose range for postoperative thyroid remnant ablation.

10 Dec 2012

Angiocidin reduces acute myeloid leukemia cells in vivo by almost two-thirds in pre-clinical studies

Angiocidin, a novel tumor-inhibiting protein, has been shown to reduce acute myeloid leukemia (AML) cells in vivo by almost two-thirds in pre-clinical experiments.

10 Dec 2012

Sanofi Pasteur’s IMOJEV vaccine against Japanese encephalitis is now available in Australia

Sanofi Pasteur, the vaccines division of Sanofi, announced today that IMOJEV vaccine against Japanese encephalitis (JE) is now available in Australia.

10 Dec 2012

Targeting RAD52 protein can block the process by which leukemia stem cells repair themselves

Despite treatment with imatinib, a successful drug that targets chronic myeloid leukemia (CML), a deadly type of cancer, some patients may continue to be at risk for relapse because a tiny pool of stem cells is resistant to treatment and may even accumulate additional genetic aberrations, eventually leading to disease progression and relapse. These leukemia stem cells are full of genetic errors, loaded with potentially lethal breaks in DNA, and are in a state of constant self-repair.

10 Dec 2012

GSK, MD Anderson partner to develop new therapeutic antibodies against cancer

The University of Texas MD Anderson Cancer Center and GlaxoSmithKline (GSK) have signed a research collaboration and license agreement to develop new therapeutic antibodies that promote an immune system attack against cancer.

10 Dec 2012

C5aRA treatment could be effective against periodontitis

Periodontitis, a form of chronic gum disease that affects nearly half of the U.S. adult population, results when the bacterial community in the mouth becomes unbalanced, leading to inflammation and eventually bone loss. In its most severe form, which affects 8.5 percent of U.S. adults, periodontitis can impact systemic health.

9 Dec 2012

Anti-seizure drug benefits women with severe morning sickness

Good news may be on the horizon for Kate Middleton, Duchess of Cambridge, and other women stricken with severe nausea and vomiting during pregnancy, thanks to the work of a University at Buffalo professor who is conducting research on a drug that is showing success treating pregnant women with this condition.

8 Dec 2012

IQWiG investigates benefits of rilpivirine for HIV treatment

Since the start of 2012, a new drug called rilpivirine has been available for adult patients infected with the human immunodeficiency virus type 1 (HIV-1). It is marketed by two different pharmaceutical companies, by one as a single agent (trade name Edurant-) and by the other as a fixed combination with other HIV drugs (trade name Eviplera-).

8 Dec 2012

New public-private partnership will allow Brazil to produce patented ARV for national treatment program

For the first time, Brazil in 2013 will enter into a new type of public-private partnership that allows the nation to produce a generic version of the antiretroviral (ARV) drug atazanavir sulphate, which will be under patent through its producer Bristol-Myers Squibb until 2017, Inter Press Service reports.

8 Dec 2012

More compounding pharmacies closed as new infections are reported

Massachusetts orders the closing of three more pharmacies, while health officials in at least two states report additional infections from contaminated steroids, although the latest cases are not life-threatening.

7 Dec 2012

Marijuana legalization in 2 states comes under microscope

The New York Times reports the Justice Department and senior White House officials are debating legal action against Colorado and Washington, which could undermine voter-approved initiatives. Meanwhile, a USA Today/Gallup Poll shows Americans are divided on decriminalization efforts but believe the federal government should not intervene after states vote to take that step.

7 Dec 2012

Study finds longer course of tamoxifen treatment cuts breast cancer deaths

The finding that women should be taking the drug for twice as long as is now customary came out of study of nearly 7,000 women from 36 countries.

7 Dec 2012

IRIN examines WHO's efforts to communicate HIV risk among injectable hormonal contraceptive users

IRIN examines the WHO's ongoing efforts to synthesize and communicate guidance about the risk of HIV infection and transmission for women taking injectable hormonal contraception, including a meeting scheduled for this week in Geneva.

7 Dec 2012

Meda signs agreement to acquire MidNite OTC sleep-aid product

Meda has signed an agreement to acquire MidNite, an OTC sleep-aid product. MidNite is well established in the U.S. and holds a market leading position within a growing category. Annualized revenues for MidNite are approximately 100 MSEK.

7 Dec 2012

Statins improves progression-free survival in patients with inflammatory breast cancer

Researchers from The University of Texas MD Anderson Cancer Center found statins, the commonly used drug to lower cholesterol, improved progression-free survival in patients with inflammatory breast cancer (IBC).

6 Dec 2012

Global Post examines unproven, unscientific HIV treatments

Global Post examines how "many HIV patients around the world continue to turn to more affordable but far less reliable treatments" instead of proven -- but more expensive -- therapies, such as antiretroviral (ARV) drugs.

6 Dec 2012

Studies gauge health law's impact on consumer savings, Rx drug coverage

The Commonwealth Fund concluded that consumers saved $1.5 billion in 2011 as a result of a provision that limits how much insurers can spend on expenses not related to medical care. Meanwhile, Avalere Health found that drug coverage plans offered on health exchanges will vary by state.

6 Dec 2012

Bayer submits MAA in Europe for EYLEA to treat macular edema after CRVO

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that Bayer HealthCare has submitted an application for marketing authorization in Europe for EYLEA (aflibercept) Injection for the treatment of macular edema following Central Retinal Vein Occlusion (CRVO).

6 Dec 2012

Study questions value of coated, low-dose aspirin therapy

Roughly one-fifth of Americans take low-dose aspirin every day for heart-healthy benefits. But, based on either urine or blood tests of how aspirin blocks the stickiness of platelets - blood cells that clump together in the first stages of forming harmful clots - up to one third of patients are deemed unlikely to benefit from daily use. Such patients are called "aspirin resistant." Clots are the main cause of most heart attacks and strokes.

6 Dec 2012

Scientists evaluate two different strategies to treat Usher syndrome

After years of basic research, scientists at Johannes Gutenberg University Mainz (JGU) are increasingly able to understand the mechanisms underlying the human Usher syndrome and are coming ever closer to finding a successful treatment approach. The scientists in the Usher research group of Professor Dr. Uwe Wolfrum are evaluating two different strategies. These involve either the repair of mutated genes or the deactivation of the genetic defects using agents.

6 Dec 2012